Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joy Zou

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
International Journal of Medical Informatics|March 8, 2026
Utilizing virtual reality to improve ICU visual displaysNathan Zhang, Joy Zou, Sungmin Kwon, et al.
Frontiers in Endocrinology|February 8, 2021
Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic ParagangliomaSriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero, et al.
Frontiers in Endocrinology|October 27, 2023
Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [<sup>177</sup>Lu]Lu-DOTA-TATE therapySriram Gubbi, Mohammad Al-Jundi, Sungyoung Auh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2025
Erratum: Phase II Study of <sup>177</sup>Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and BiomarkersFrank I Lin, Jaydira Del Rivero, Jorge A Carrasquillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2025
Phase II Study of <sup>177</sup>Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and BiomarkersFrank I Lin, Jaydira Del Rivero, Jorge A Carrasquillo, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
International Journal of Medical Informatics|March 8, 2026
Utilizing virtual reality to improve ICU visual displaysNathan Zhang, Joy Zou, Sungmin Kwon, et al.
Frontiers in Endocrinology|February 8, 2021
Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic ParagangliomaSriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero, et al.
Frontiers in Endocrinology|October 27, 2023
Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [<sup>177</sup>Lu]Lu-DOTA-TATE therapySriram Gubbi, Mohammad Al-Jundi, Sungyoung Auh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2025
Erratum: Phase II Study of <sup>177</sup>Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and BiomarkersFrank I Lin, Jaydira Del Rivero, Jorge A Carrasquillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2025
Phase II Study of <sup>177</sup>Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and BiomarkersFrank I Lin, Jaydira Del Rivero, Jorge A Carrasquillo, et al.
Pageof 1